CCN2 expression and localization in melanoma cells

Abstract   The matricellular protein connective tissue growth factor (CTGF, CCN2) is overexpressed in several forms of cancer and may represent a novel target in anti-cancer therapy. However, whether CCN2 is expressed in melanoma cells is unknown. The highly metastatic murine melanoma cell line B16(F10) was used for our studies. Real time polymerase chain reaction analysis was used to detect mRNA expression of CCN1, CCN2, CCN3 and CCN4 in Western blot and immunofluorescence analyses were used to detect CCN2 protein. Inhibitors of signal transduction cascades were used to probe the mechanism underlying CCN2 expression in B16(F10) cells. CCN2 was expressed in B16(F10) cells, and was reduced by the FAK/src inhibitor PP2 and the MEK/ERK inhibitor U0126 indicating that CCN2 acts downstream of these pathways in B16(F10) murine melanoma cells. Expression of CCN1, CCN3 and CCN4 was not reduced by PP2 or U0126; in fact, expression of CCN4 mRNA was elevated by PP2 or U0126 treatment. To our surprise, CCN2 protein was detected in the nuclei of B16(F10) cells, and was undetectable in the cytoplasm. CCN2 was expressed in B16(F10) melanoma cells, adding to the list of cancer cells in which CCN2 is expressed. Of the CCN family members tested, only CCN2 is downstream of the highly oncogenic MEK/ERK pathway. CCN2 should be further evaluated for a possible role in melanoma growth and progression.

• Content Type Journal Article
• Pages 219-226
• DOI 10.1007/s12079-011-0128-0
• Authors
  • Wei Sha, Department of Dentistry, Schulich School of Medicine of Dentistry, Dental Sciences Building, University of Western Ontario, London, ON, Canada N6A 5C1
  • Andrew Leask, Department of Dentistry, Schulich School of Medicine of Dentistry, Dental Sciences Building, University of Western Ontario, London, ON, Canada N6A 5C1

• Journal Journal of Cell Communication and Signaling
• Online ISSN 1873-961X
• Print ISSN 1873-9601
• Journal Volume Volume 5
• Journal Issue Volume 5, Number 3